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Abstract. Esophageal cancer (EC) has a globally increasing 
incidence with poor curative treatment options and survival 
rates. Environmental and dietary factors have crucial roles in 
esophageal carcinogenesis. Polymorphisms in the UGT genes, 
a superfamily of enzymes essential for the detoxification of 
carcinogens, may alter enzyme activity and subsequently 
may play a role in EC etiology. Rather than solely estab-
lishing differences in genotype distribution, we investigated 
whether functional polymorphisms in UGT genes that can 
predict enzyme activity in vivo, may influence EC risk. A 
case-control study including 351 Caucasian EC patients and 
592 Caucasian controls was conducted and polymorphisms 
in seven UGT genes were determined, using the polymerase 
chain reaction. On the basis of allelic in vitro enzyme activity 
measurements, genotypes were categorized according to their 
predicted in vivo enzyme activity into high, medium and low 
categories. Predicted enzyme activity groups were combined 
and compared between patients and controls. The UGT1A1 
and UGT1A8 predicted high enzyme activity genotypes were 
significantly more (OR=1.62; 95% CI, 1.02-2.56) and less 
frequent (OR=0.36; 95% CI, 0.15-0.84) among patients with 
esophageal squamous cell carcinoma (ESCC), respectively. 
High (OR=0.42; 95% CI, 0.22-0.84) and medium (OR=0.25; 
95% CI, 0.12-0.52) activity UGT2B4 genotypes were signifi-
cantly less often present in ESCC patients. No association was 
detected between UGT genotypes and esophageal adenocar-
cinoma (EAC) risk. Polymorphisms in UGT genes, resulting 
in altered enzyme activity genotypes, do not seem modifiers 
of EAC risk. However, the predicted high activity UGT1A1 
genotype, associated with low serum levels of the antioxidant 
bilirubin, was associated with an increased ESCC risk. The 
UGT1A8 and UGT2B4 genotypes associated with decreased 
predicted enzyme activities, were significantly associated with 
an increased risk of ESCC, probably by a decreased detoxifi-
cation of carcinogens.
Introduction
Esophageal cancer (EC) is the eighth most common neoplasm 
in the world with poor 5-year survival rates of 16% in the 
USA and 10% in Europe (1). Esophageal squamous cell carci-
noma (ESCC) is more prevalent in Asia, whereas esophageal 
adenocarcinoma (EAC) is predominantly seen in the Western 
world (2). Known risk factors for ESCC are the use of alcohol, 
tobacco or local dietary habits (3), whereas obesity and gastro-
esophageal reflux disease as a result of a Western lifestyle are 
risk factors for EAC (4). Differences in genetic predisposi-
tion can also influence the individual risk profile. Genetic 
polymorphisms in detoxification enzymes may influence the 
process of carcinogenesis by altering the enzyme activity and 
subsequently influence the degree of exposure to carcinogens.
Detoxification occurs through phase I and phase II biotrans­
formation reactions. A major phase II reaction is glucuronidation, 
catalyzed by the UDP-glucuronosyltransferases (UGTs) (5). This 
superfamily of detoxification enzymes catalyzes the glucuro­
nidation of small lipophilic agents into more water soluble 
compounds which are subsequently secreted via bile or urine (5).
Human UGTs consist of two main gene families, UGT1 
and UGT2. Xenobiotics such as phenolic compounds, flavones 
and amines are substrates for the UGT1A family, whereas 
UGT2B enzymes prefer endogenous substrates including 
steroids, opioids and bile acids (5,6). In the human esophagus 
at least seven UGT enzymes of the UGT1A and UGT2B family 
are expressed (7).
Lacko et al found that polymorphisms resulting in higher 
activities of UGT1A1 were associated with an increased risk of 
head and neck cancer (8). Furthermore, Zheng et al concluded 
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that low-activity UGT1A7 genotypes were associated with an 
increased orolaryngeal cancer risk, especially in smokers (9). 
Vogel et al described that the UGT1A7*3 allele, exhibiting 
reduced carcinogen detoxification activity, was significantly 
associated with proximal gastrointestinal cancer (10). This last 
study was probably flawed since the over­representation of the 
UGT1A7*3 allele was due to PCR-dependent bias (11,12).
There is a gap in the literature with respect to UGT poly-
morphisms and the risk for EC. Given the fact that head 
and neck cancer and esophageal cancer share identical risk 
factors (13), it may be highly relevant to investigate whether 
polymorphisms in UGT genes that are associated with head 
and neck cancer, are also associated with esophageal cancer 
risk.
Rather than to solely compare polymorphism distribution 
between patients and controls, we set out to examine whether 
UGT genotypes, associated with altered enzyme activity, 
modify EC risk. We conducted a case-control study and deter-
mined functional polymorphisms in seven UGT genes.
Materials and methods
Patients and controls. The study was approved by the Medical 
Ethical Review Committee, region Arnhem-Nijmegen (CMO 
2002/114). Informed consent was obtained from all partici-
pants. Blood or tissue samples from 351 Caucasian patients 
with esophageal cancer were collected in the period October 
2002 to March 2011 from four different hospitals, localized 
within 30 km distance in the South-East area of the Netherlands 
(14). Only patients with a diagnosis of esophageal carcinoma 
as confirmed by a pathologist were included in the study. As a 
source of DNA, in 92 cases tissue biopsies of normal esophagus 
or stomach from EC patients was collected after surgery, 
whereas in the other 259 cases EDTA blood was collected. 
Blood and tissue samples were frozen at ­20˚C and ­80˚C, 
respectively. DNA isolation was performed by usage of the 
High Pure PCR Template Preparation Kit (Roche, Mannheim, 
Germany) according to the instructions of the manufacturer. 
Post extraction DNA was stored at 4˚C. Caucasian healthy 
controls (n=592) were recruited from the same geographical 
area of the Netherlands, after advertisement in local papers, 
as described by Kristinsson et al (14). Controls were matched 
with the EC patients for age, ethnicity and gender.
Genotyping methods and allelic in vitro enzyme activity. The 
selection of UGT enzymes was based upon either esopha-
geal expression or relevance to head and neck carcinoma, as 
esophageal cancer shares some of the relevant risk factors. 
Expression in the esophagus of the UGT1A6, 1A7, 1A8 and 
UGT2B4 enzymes has been detected (5,15,16), while UGT1A1, 
UBT2B7 and UGT2B17 are known to be highly expressed in 
liver and intestine and thus may indirectly modify esophageal 
cancer risk (16).
UGT1A1. The microsatellite polymorphism of the TATA box 
in the promoter region of the UGT1A1 gene (UGT1A1*28, 
rs8175347) was analyzed using the polymerase chain reaction 
(PCR) followed by polyacrylamide gel electrophoresis as 
described before (8). The TA repeat polymorphism created the 
*28 allele associated with a low enzyme activity (8,17).
UGT1A6. The T181A (rs2070959) and R184S (rs1105879) 
polymorphisms in exon 1 of the UGT1A6 gene were studied 
by PCR followed by restriction fragment length polymor-
phism (PCR-RFLP) analysis (18). These polymorphisms 
express an enzyme with a lower catalytic activity (19). Only 
the frequencies for the T181A mutation are shown. The R184S 
SNP corresponds to >90% with these frequencies. However, 
because of separate analyses for these SNP's, the *1*2 genotype 
could not be determined.
UGT1A7 alleles were genotyped for the polymorphisms 
at codon 129 (rs17868323) and 131 (rs17868324) by melting 
curve analysis with fluorescence resonance energy transfer 
(FRET) probes on the iCycler (Bio-Rad Laboratories BV; 
Hercules CA) and by PCR-RFLP for detection of the W208R 
(rs11692021) polymorphism, as described elsewhere (20). The 
identified UGT1A7*1, *2, *3 and *10 alleles were categorized in 
enzyme activity categories as described by Guillemette et al 
(21).
UGT1A8. The polymorphisms UGT1A8*2 (rs1042597) and 
UGT1A8*3 (rs17863762) were determined using PCR-RFLP 
analysis, as described before (22). The two polymorphisms 
resulted in three allelic variants of the UGT1A8 gene (23). 
Since the UGT1A8*1 and *2 alleles differ little in function and 
the UGT1A8*3 allele displays no catalytic activity (23), geno-
types were stratified into high (*1*1, *1*2, *2*2) and medium/
low activity (*1*3, *2*3, *3*3) genotypes for analyses.
UGT2B4/UGT2B7. A dual-colour allele-specific assay was 
used for genotyping the polymorphisms at codon 458 of the 
UGT2B4 gene (rs13119049) and codon 268 of the UGT2B7 
gene (rs7439366) PCR was performed on the iCycler 
iQ Multicolour Real-Time Detection System (Bio-Rad 
Laboratories) as describe before (24,25). Genotypes were 
assigned using the iCycler iQ Optical System Software version 
3.1. At each PCR run (in 96-well plates) in several wells 
sterile H2O instead of genomic DNA was added as negative 
controls for amplification. The UGT2B4 polymorphism may be 
responsible for differences in substrate specificity and catalytic 
activity (26,27). Furthermore, although the H268Y amino-acid 
alteration creating the UGT2B7*2 allele does not produce a 
significant difference in enzyme activity (28), we still catego-
rized the UGT2B7 genotypes in predicted activity groups with 
the premise that the mutated allele produces a lower activity.
UGT2B17. The 150-kb deletion in UGT2B17 was detected as 
described by Wilson et al (29). It has been demonstrated that 
due to the UGT2B17 deletion polymorphism, genotypes with 
at least one null allele (UGT2B17*2) produces a lower level of 
glucuronidation (30).
Statistical analyses. The selected functional polymorphisms 
are known to produce alleles expressing differential in vitro 
enzyme activity. On the basis of this in vitro  enzyme activity, 
the various genotypes were categorized into three groups of 
predicted in vivo enzyme activity: high, medium and low. 
In our study, for the purpose of increasing the power, the 
combined group of low and intermediate activity was used as 
reference in the comparison between patients with ESCC or 
EAC and controls.
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Haplotypes were generated using the PLEM program (31). 
The haplotype with none of the mutations was set as a reference 
in the comparison between cases and controls. Only partici-
pants with complete genotypes were included in the haplotype 
analyses.
The independent samples t-test was applied for the differ-
ences in continues variables between characteristics of patients 
and controls. The χ2 test was used for analyzing nominal vari-
ables of patient characteristics and to test for differences of 
frequencies in predicted enzyme activity genotypes between 
two groups. Odds ratios (OR) with 95% confidence interval 
(95% CI) were calculated. Stratified analyses were performed 
according to tumor histology. All P-values were two-sided and 
a probability level of P<0.05 was considered to be significant. 
All analyses were performed with the software SPSS for 
Windows, version 16.0 (SPSS Inc., Chicago, IL, USA).
Table I. Characteristics of patients with esophageal cancer and controls.
 Patients -------------------------------------------------------------------------------------------------------------------
Characteristics ESCC EAC Total Controls
No. (% of total) 85 (24.2) 260 (74.1) 351 (100)a 592
Age (years; mean ± SD) 63.7±10.3 65.3±11.1 65.0±10.9 63.4±11.9
Gender
 Male 56 (65.9) 221 (85.0) 282 (80.3) 478 (80.7)
 Female 28 (32.9) 39 (15.0) 68 (19.4) 114 (19.3)
aNote that for 6 patients the exact tumor type was not mentioned in the pathology report, whereas for 1 patient the gender is unknown. ESCC, 
esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma.
Table II. UGT gene distribution stratified in predicted enzyme activity in patients with esophageal cancer and controls.
  Predicted enzyme ESCC EAC Controls
UGT isozymes UGT genotypesa activity in vivo (n=85) [n (%)] (n=260) [n (%)] (n=592) [n (%)]
UGT1A1 *1*1 High activity 50 (58.8) 122 (46.9) 276 (46.6)
 *1*28 Medium activity 30 (35.3) 102 (39.2) 256 (43.2)
 *28*28 Low activity 5 (5.9) 33 (12.7) 56 (9.5)
UGT1A6 *1*1 High activity 42 (49.4) 119 (45.8) 272 (45.9)
 *1*2 Medium activity 37 (43.5) 109 (41.9) 249 (42.1)
 *2*2 Low activity 6 (7.1) 31 (11.9) 71 (12.0)
UGT1A7 *1*1, *1*2, *2*2 High activity 33 (38.8) 101 (38.8) 228 (38.5)
 *1*3, *1*4, *1*10, *2*3 Medium activity 43 (50.6) 110 (42.3) 274 (46.3)
 *3*3, *3*4, *3*10, *4*4 Low activity 9 (10.6) 49 (18.8) 90 (15.2)
UGT1A8 *1*1, *1*2, *2*2 High activity 77 (90.6) 247 (95.0) 565 (95.4)
 *1*3, *2*3 Medium activity 7 (8.2) 9 (3.5) 16 (2.7)
 *3*3 Low activity 0 (0.0) 0 (0.0) 3 (0.5)
UGT2B4 *1*1 High activity 50 (58.8) 139 (53.5) 320 (54.1)
 *1*2 Medium activity 21 (24.7) 100 (38.5) 233 (39.4)
 *2*2 Low activity 14 (16.5) 21 (8.1) 38 (6.4)
UGT2B7 *1*1 High activity 18 (21.2) 59 (22.7) 133 (22.5)
 *1*2 Medium activity 42 (49.4) 128 (49.2) 298 (50.3)
 *2*2 Low activity 24 (28.2) 73 (28.1) 161 (27.2)
UGT2B17 *1*1 High activity 54 (63.5) 174 (66.9) 353 (59.6)
 *1*2 Medium activity 22 (25.9) 62 (23.8) 179 (30.2)
 *2*2 Low activity 9 (10.6) 24 (9.2) 54 (9.1)
aThe genotypes were classified into the three activity categories according to the observed allelic activity in vitro, as described in the Materials 
and methods.
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Results
Demographics and genotype distribution. We included a total 
of 351 patients with esophageal cancer and 592 controls in 
our study. There was no statistical difference between the two 
groups regarding race, age and gender (Table I). However, the 
gender distribution differed significantly with females being 
more frequent in the ESCC group in comparison to the EAC 
group (32.9 vs. 15.0%; P<0.001). Genotype frequencies of 
UGT1A8 G→A in controls (P<0.001) and the UGT2B17 dele-
tion polymorphism in controls (P<0.001) were not distributed 
according to the Hardy-Weinberg equilibrium.
Table II displays the distribution of the genetic polymor-
phisms in UGTs, along with the genotype distribution and 
the predicted enzyme activities, for controls and patients with 
ESCC and EAC, as well as for all cancer patients. Due to PCR 
bias not all genotypes could be generated.
Enzyme activities and haplotype distribution. Table III and 
Fig. 1 illustrate that none of the high activity UGT genotypes 
modified EAC risk in our population. Additionally Fig. 2 
demonstrates that the high activity genotypes of UGT1A1 and 
UGT1A8, respectively, increase and decrease ESCC suscep-
tibility. The frequency of the predicted high enzyme activity 
UGT1A1 genotype was significantly higher in the ESCC 
patients in comparison to the predicted low and medium 
enzyme activity genotypes (OR=1.62; 95% CI, 1.02-2.56) 
(Table III). The UGT1A8 predicted high activity genotype 
was significantly less frequent among ESCC patients than in 
controls (OR=0.36; 95% CI, 0.15-0.84). Furthermore, the high 
Table III. UGT genotypes and associated predicted enzyme activity with corresponding odds ratios (OR) for patients with ESCC, 
EAC and EC compared to controls.
UGT Predicted enzyme ESCC  EAC  Controls
isozymes activity n=85 [n (%)] OR (95% CI) n=260 [n (%)] OR (95% CI) n=592 [n (%)]
UGT1A1 Low/medium 35 (41.2) Ref 135 (51.9) Ref 312 (52.7)
 High 50 (58.8) 1.62 (1.02-2.56) 122 (46.9) 1.02 (0.76-1.37) 276 (46.6)
UGT1A6 Low (*2*2) 6 (7.1) Ref 31 (11.9) Ref 70 (11.8)
 High (*1*1) 40 (47.1) 1.8 (0.74-4.47) 112 (43.1) 0.99 (0.61-1.59) 256 (43.2)
UGT1A7 Low/medium 52 (61.2) Ref 159 (61.2) Ref 364 (61.5)
 High 33 (38.8) 1.01 (0.64-1.62) 101 (38.8) 1.01 (0.75-1.37) 228 (38.5)
UGT1A8 Low/medium 7 (8.2) Ref 9 (3.5) Ref 19 (3.2)
 High 77 (90.6) 0.37 (0.15-0.91) 247 (95.0) 0.92 (0.41-2.07) 565 (95.4)
UGT2B4 Low/medium 35 (41.2) Ref 121 (46.5) Ref 271 (45.8)
 High 50 (58.8) 1.21 (0.76-1.92) 139 (53.5) 0.97 (0.73-1.30) 320 (54.1)
UGT2B7 Low/medium 66 (77.6) Ref 201 (77.3) Ref 459 (77.5)
 High 18 (21.2) 0.94 (0.54-1.64) 59 (22.7) 1.01 (0.72-1.44) 133 (22.5)
UGT2B17 Low/medium 31 (36.5) Ref 86 (33.1) Ref 233 (39.4)
 High 54 (63.5) 1.15 (0.72-1.84) 174 (66.9) 1.34 (0.98-1.82) 353 (59.6)
Figure 1. High activity UGT genotypes and EAC risk. Figure 2. High activity UGT genotypes and ESCC risk.
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enzyme activity UGT2B4 genotype did not modify ESCC 
risk when set off against the combined low and intermediate 
activity group. However, the high (OR=0.42; 95% CI, 0.22-
0.84) and medium (OR=0.25; 95% CI, 0.12-0.52) activity 
UGT2B4 genotypes when set off against the low enzyme 
activity genotypes, were significantly less often present in 
ESCC in comparison to controls.
Tables IV and V show the UGT1 and UGT2 haplotype 
distribution between EAC or ESCC patients and controls, 
respectively. Setting the haplotype with no mutations as a 
reference, no UGT1 haplotype modified EAC or ESCC risk. 
Regarding the UGT2 haplotypes, the combination of mutations 
in the UGT2B7 and UGT2B17 genes (011) was significantly 
associated with a decreased ESCC risk (OR=0.52; 95% CI, 
0.29-0.94). Similarly, only a mutation in the UGT2B4 gene 
(100) decreased risk of ESCC (OR=0.60; 95% CI, 0.34-1.05). 
However, the latter correlation was not significant.
Discussion
This study detected the predicted high activity UGT1A1 
genotype to be associated with an increased ESCC risk. The 
UGT1A1*28 polymorphism in the promoter region of UGT1A1 
is well studied in relation to glucuronidation of bilirubin (17), 
in its protective role in coronary artery disease (32) and in the 
risk of head and neck cancer (8). Nevertheless a potential role 
of the low activity UGT1A1*28 allele in the risk of esophageal 
cancer has not been investigated before. Our results correspond 
with those obtained by Lacko et al in a case control study with 
head and neck cancer patients (8), where an inverse correlation 
between the low activity UGT1A1*28*28 genotype and the 
risk of squamous cell carcinoma was found. The low activity 
genotype may be associated with lower risk for ESCC, due to 
the lower levels of glucuronidation, resulting in higher serum 
bilirubin levels (8,17). This is most likely a systemic effect, as 
Table IV. UGT1 haplotypes with corresponding odds ratios (OR) for patients with ESCC and EAC compared to controls.
UGT1 ESCC  EAC  Controls
haplotypes n=170 [n (%)] OR (95% CI) n=520 [n (%)] OR (95% CI) n=1184 [n (%)]
1111100 34 (20.0) 0.72 (0.43±1.21) 141 (27.1) 1.20 (0.86±1.66) 287 (24.2)
0000010 36 (21.2) 0.94 (0.56±1.57) 111 (21.4) 1.16 (0.82±1.63) 234 (19.8)
0000000 32 (18.8) Ref 80 (15.4) Ref 195 (16.5)
0001000 26 (15.3) 0.99 (0.57±1.73) 82 (15.8) 1.25 (0.86±1.81) 160 (13.5)
0001010 6 (3.5) 0.65 (0.26±1.64) 17 (3.3) 0.74 (0.41±1.35) 56 (4.7)
0001100 8 (4.7) 0.94 (0.41±2.16) 21 (4.0) 0.98 (0.56±1.74) 52 (4.4)
0111100 10 (5.9) 1.35 (0.62±2.96) 20 (3.9) 1.08 (0.60±1.95) 45 (3.8)
1001100 1 (0.6) 0.24 (0.03±1.86) 9 (1.7) 0.88 (0.39±1.96) 25 (2.1)
0001101 5 (2.9) 2.03 (0.69±5.98) 7 (1.4) 1.14 (0.45±2.89) 15 (1.3)
0110000 2 (1.2) 0.94 (0.20±4.35) 1 (0.2) 0.19 (0.02±1.46) 13 (1.1)
0011000 1 (0.6) 0.51 (0.06±4.04) 6 (1.2) 1.22 (0.44±3.36) 12 (1.0)
Haplotypes are in the following order: UGT1A1, UGT1A6 (T181A), UGT1A6 (R184S), UGT1A7 (N129K/R131K), UGT1A7 (W208R), 
UGT1A8 (A173G) and UGT1A8 (C277Y). 0, no mutation; 1, mutation.
Table V. UGT2 haplotypes with corresponding odds ratios (OR) for patients with ESCC and EAC compared to controls.
UGT2 ESCC  EAC  Controls
haplotypes n=170 [n (%)] OR (95% CI) n=520 [n (%)] OR (95% CI) n=1184 [n (%)]
010 61 (35.9) 1.04 (0.69±1.57) 147 (28.3) 1.03 (0.77±1.37) 351 (29.7)
000 47 (27.7) Ref 115 (22.1) Ref 282 (23.8)
100 19 (11.2) 0.60 (0.34±1.05) 90 (17.3) 1.16 (0.83±1.62) 190 (16.1)
011 16 (9.4) 0.52 (0.29±0.94) 75 (14.4) 0.99 (0.70±1.40) 185 (15.6)
110 16 (9.4) 1.30 (0.70±2.42) 45 (8.7) 1.49 (0.97±2.29) 74 (6.3)
001 9 (5.3) 0.95 (0.44±2.04) 29 (5.6) 1.25 (0.76±2.05) 57 (4.8)
101 1 (0.6) 0.17 (0.02±1.28) 14 (2.7) 0.98 (0.51±1.89) 35 (3.0)
111 1 (0.6) 0.60 (0.08±4.80) 5 (1.0) 1.23 (0.41±3.67) 10 (0.8)
Haplotypes are in the following order: UGT2B4, UGT2B7 and UGT2B17. 0, no mutation; 1, mutation.
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the UGT1A1 enzyme is not expressed in the esophagus (5). 
Bilirubin acts as an antioxidant by inhibiting cellular damage 
induced by alcohol and smoking related oxidative stress 
(32,33). So the hypothesis that serum bilirubin protects against 
ESCC by inhibiting damage induced by reactive oxygen 
species (ROS), is further encouraged because the correlation is 
not found in patients with EAC. The latter histological subtype 
has different risk factors (4).
Genetic polymorphisms in the UGT1A6 gene have been 
studied regarding the association with aspirin use in relation 
to colorectal adenomas or carcinoma (34), as aspirin and other 
non­steroidal anti­inflammatory drugs (NSAIDs) are reported 
to have protective effects on colorectal- or esophageal tumori-
genesis (35). Zheng et al reported UGT1A7*3 to be a risk allele 
in patients with orolaryngeal cancer (9), although controversy 
still exists as Lacko et al reported different results (20). For 
both UGTs however, correlations with esophageal cancer risk 
were not previously explored, but this study did not demon-
strate correlations between UGT1A6 or UGT1A7 genotypes 
and EAC or ESCC risk.
Our analyses illustrates a significantly more common 
occurrence of the low/medium activity UGT1A8 genotypes 
in ESCC patients in comparison to controls. This identifies 
UGT1A8*3 as a high risk allele in the etiology of esophageal 
SCC, although homozygosity for this allele was not found in 
patients. The genotype distribution in the controls was not 
according the Hardy-Weinberg (HW) equilibrium. This may 
be a by chance finding due to rarity of the UGT1A8*3 polymor-
phism. Non-random mating, selection or migration within the 
control population may be also responsible for the HW disequi-
librium. Furthermore, although linkage disequilibrium exists 
within the UGT1 gene as the UGT genes are closely grouped 
on the same chromosome, the UGT1 haplotypes illustrated 
that linkage had limited influence on the UGT1A8 correla-
tion. Another explanation for this correlation may be the high 
substrate diversity of the UGT1A8 isozyme (36). An alteration 
in its function can highly manipulate the detoxification rate of 
carcinogenic compounds in the gastrointestinal tract. A key 
example is the glucuronidation of PhIP, an amine formed in 
cooked meat and fish and metabolized by phase I biotransfor-
mation cytochrome P450 enzymes (37). Heterocyclic amines 
are associated with colorectal carcinoma, breast cancer and 
bladder carcinoma (38-40). Another essential group of carcin-
ogens found in red meat and tobacco smoke, are the N-nitroso 
compounds (NOC), also eliminated by the UGT1A8 isozyme 
(41), which could further explain the role of the low activity 
UGT1A8*3 allele in esophageal SCC risk. Furthermore, our 
results showed no differences in the distribution of the high 
activity UGT2B4 genotype between patients and controls, 
when set off against the combined low and medium group. 
However, the low and medium activity genotypes were more 
and less frequent in ESCC patients in comparison to controls, 
respectively. This was not confirmed by the histology based 
stratified analyses. The lower frequency of the UGT2B4 
medium activity genotype in ESCC patients, was confirmed 
by the haplotype analyses as the 100 haplotype had a tendency 
to decrease ESCC risk (OR=0.60; 95% CI, 0.34-1.05). The 
comparison methodology, which obliges the combination of 
the low and the medium groups, nullifies the original differ-
ence in distribution of the UGT2B4 genotypes between ESCC 
patients and controls. Indeed, the high (OR=0.42; 95% CI, 
0.22-0.84) and the medium (OR=0.25; 95% CI, 0.12-0.52) 
activity UGT2B4 genotypes were significantly less present in 
ESCC patients when set off against the low activity genotype. 
This establishes the low activity UGT2B4*2 allele to be a 
risk factor for ESCC. The UGT2B4 isozyme is involved in 
eliminating eicosanoids (42), compounds derived from fatty 
acid oxygenation. This is a reaction by which ROS are released 
and which is catalyzed by cyclooxygenases and lipoxygenases 
to produce prostanoids and leukotrienes, respectively. These 
metabolites play an important role in cell proliferation, 
inflammation and angiogenesis, all vital processes for the 
development of neoplasms (43,44). One could postulate that 
modifications in the detoxification process of eicosanoids 
can shift the tissue equilibrium towards carcinogenesis in 
the esophagus. However, this also may be a systemic process, 
since esophageal epithelium probably does not express the 
UGT2B4 isozyme (5,16).
Oddly we could not verify the significant correlation for 
EAC patients, given the UGT2B4 involvement in the conjuga-
tion of bile acids (42). Capello et al suggested that bile acids 
can provoke an inflammatory reaction in Barrett's epithelium 
(45). Although the UGT2B4*2 allele does not seem to play 
an important part in the etiology of EAC, its role in Barrett's 
esophagus is yet to be examined. One could argue that the less 
active allele could negatively influence the bile acid detoxific­
ation process and could stimulate the development of Barrett's 
epithelium.
Lastly, our results show that polymorphisms in UGT2B7 
and UGT2B17 do not seem implicated in the etiology of 
esophageal cancer. Although the UGT2B7 isozyme has a 
significant role in the metabolism of frequently used drugs 
(28,46,47), there is an expected minor difference in predicted 
activity between the two alleles. For UGT2B17 however, 
there was a tendency for the high enzyme activity genotype 
to be more present in the EAC patients in comparison to 
controls (OR=1.29; 95% CI, 0.98-1.70). Furthermore, several 
studies reported a gender difference in the expression of the 
UGT2B17 deletion allele associated with a lower catalytic 
activity, resulting in a significant correlation with increased 
lung adenocarcinoma risk in women due to a decreased 
NNAL (metabolite of the tobacco-specific nitrosamine 
carcinogen NNK) glucuronidation rate (48,49). We could not 
confirm such an outcome. After stratifying for gender, no 
differences in predicted enzyme activity were found between 
the groups.
In conclusion, the notion that variations in genes of 
detoxification enzymes can influence carcinoma risk, may 
contribute to the elucidation of the EC etiology. In this study 
predicted high activity UGT1A1 genotype, low activity 
UGT1A8 and low and medium UGT2B4 genotypes were 
found to increase ESCC risk. However, these polymorphisms 
in UGT genes do not associate with EAC risk, which may 
be due to a different etiological mechanism. Unfortunately, 
the small size of our ESCC population, since ESCC is rare 
in the Netherlands, and the multiple testing due to numerous 
enzyme analyses, disable us from firmly establishing the 
above findings. Moreover, multivariate analyses that take 
dietary and lifestyle related factors into account should also 
be performed. An aim of this study is, to help create a genetic 
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profile that can predict severe risk and subsequently could 
guide the implementation of potential surveillance programs 
in order to detect tumors at an early stage, as early stage 
diagnosis would dramatically increase the overall survival of 
esophageal cancer patients.
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